PCM
PRME icon

Penserra Capital Management’s Prime Medicine PRME Stock Holding History

Penserra Capital Management’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-18,468
Closed -$176K – 1339
2023
Q3 		$176K Buy
18,468
+10,361
+128% +$135K ﹤0.01% 776
2023
Q2 		$118K Buy
8,107
+1,107
+16% +$15.5K ﹤0.01% 911
2023
Q1 		$86K Sell
7,000
-570
-8% -$9.29K ﹤0.01% 792
2022
Q4 		$140K Buy
+7,570
New +$137K ﹤0.01% 755

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Penserra Capital Management's PRME Position: Q4 2023 in Review

Penserra Capital Management sold out of Prime Medicine (PRME) in Q4 2023, closing a stake of 18,468 shares — an estimated $176K sold.

Penserra Capital Management first reported a position in PRME in Q4 2022 and held it in 4 quarters. The position peaked at $176K in Q3 2023. 105 funds tracked by Wall St. Rank hold PRME as of Q4 2023.

  • Penserra Capital Management reported no remaining Prime Medicine position as of Q4 2023 after selling out during the quarter.
  • Penserra Capital Management sold 18,468 Prime Medicine shares in Q4 2023, an estimated $176K.
  • Penserra Capital Management first reported a position in Prime Medicine in Q4 2022 and held it in 4 quarters.
  • Penserra Capital Management's Prime Medicine position peaked at $176K in Q3 2023.
  • 105 funds tracked by Wall St. Rank held Prime Medicine as of Q4 2023.

Based on Penserra Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.